- The company has developed unique technology for administering certain drugs subcutaneously at home, rather than through IV in a clinic.
- The uptake of this is receiving an impulse as Grifols, a big name in IV, is shifting towards SC and the pandemic underlines the advantage of at home administration.
- More PIDD and CIDP drugs are likely to become available for SC administration.
- While we’re still bullish, the shares seem fully valued limiting the immediate upside.
KORU Is Getting Tailwind From A Shift Away From IV And The Pandemic
June 13th, 2020 · No Comments